Company Noile-Immune Biotech Inc.

Equities

4893

JP3759560000

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per region

EPS Revisions

Annual profits - Rate of surprise

Sector Bio Therapeutic Drugs

Delayed Japan Exchange Other stock markets 07:31:30 30/05/2024 am IST			5-day change	1st Jan Change
122 ^JPY	-1.61%		-4.69%	-42.45%

2023	Certain Shares of Noile-Immune Biotech Inc. are subject to a Lock-Up Agreement Ending on 24-DEC-2023.	CI
2023	Jefferies Adjusts Noile-Immune Biotech's Price Target to 440 Yen From 800 Yen, Keeps at Buy	MT

Noile-Immune Biotech Inc is a Japan-based company mainly engaged in the development of chimeric antigen receptor T (CAR-T) cell therapy for solid tumors using proprietary technology. The Cancer Immunotherapy Drug Discovery Business segment develops various gene-modified immuno-cell therapies for the treatment of solid tumors, mainly by combining PRIME technology, a platform technology, with therapeutic technologies targeting various antigens expressed by solid tumors. The Company establishes a hybrid business model with two business models: in-house drug discovery, in which the company takes the initiative in drug discovery, and joint pipeline, in which PRIME technology is licensed to other companies for drug development.

Number of employees: 28

JPY in Million	2022	Weight	2023	Weight	Delta
Cancer Immunotherapy Drug 100.0 %	626	100.0 %	317	100.0 %	-49.37%

JPY in Million	2022	Weight	2023	Weight	Delta
Japan 100.0 %	614	98.1 %	317	100.0 %	-48.37%

Managers	Title	Age	Since
Koji Tamada PSD	President	56	01/16/01
Hiroko Nagai ADM	Chief Administrative Officer	47	01/20/01
Tsutom Tokashiki BRD	Director/Board Member	42	01/15/01

Members of the board	Title	Age	Since
Philippe Fauchet BRD	Director/Board Member	65	01/20/01
Koji Tamada PSD	President	56	01/16/01
Tsutom Tokashiki BRD	Director/Board Member	42	01/15/01
Hiroko Nagai ADM	Chief Administrative Officer	47	01/20/01

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	0	43,301,765	9,385,100 ( 21.67 %)	0	21.67 %

Name	Equities	%	Valuation
Hiroko Ogihara 24.04 %	10,405,050	24.04 %	11 M ¥
TAKEDA PHARMACEUTICAL COMPANY LIMITED 18.76 %	8,119,800	18.76 %	8 M ¥
Koji Tamada 8.665 %	3,750,000	8.665 %	4 M ¥
BINEX CO., LTD. 5.263 %	2,277,825	5.263 %	2 M ¥
Kyoko Seto 4.621 %	2,000,000	4.621 %	2 M ¥
Satoshi Wada 4.552 %	1,970,000	4.552 %	2 M ¥
Hidenobu Ishizaki 3.605 %	1,560,000	3.605 %	2 M ¥
DCI Partners KK 3.118 %	1,349,200	3.118 %	1 M ¥
Ogihara Family 2.782 %	1,203,850	2.782 %	1 M ¥
Apricot Co. Ltd. /Shibuya/ 2.782 %	1,203,850	2.782 %	1 M ¥

Noile-Immune Biotech, Inc.

T&G Hamamatsucho Building 5F 2-12-10 Shibadaimon

105-0012, Tokyo

http://www.noile-immune.com

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

124 JPY

Average target price

440 JPY

Spread / Average Target

+254.84%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
NOILE-IMMUNE BIOTECH INC.	-42.45%	3.53Cr
VERTEX PHARMACEUTICALS INCORPORATED	+8.38%	12TCr
REGENERON PHARMACEUTICALS, INC.	+10.13%	10TCr
BIONTECH SE	-11.69%	2.27TCr
ARGENX SE	+2.21%	2.18TCr
GENMAB A/S	-10.88%	1.82TCr
WUXI APPTEC CO., LTD.	-41.90%	1.65TCr
BEIGENE, LTD.	-16.00%	1.6TCr
NEUROCRINE BIOSCIENCES, INC.	+2.28%	1.41TCr
SAREPTA THERAPEUTICS, INC.	+20.54%	1.07TCr

Bio Therapeutic Drugs